Motus GI Holdings, Inc.

$ Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224010314 Filed on March 18, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.944M	$4.958M	$4.958M
YoY Change	-42.83%	-64.69%	-64.69%
Cash & Equivalents	$4.900M	$5.000M	$4.958M
Short-Term Investments
Other Short-Term Assets	$497.0K	$227.0K	$227.0K
YoY Change	-54.53%	-70.93%	-70.93%
Inventory	$479.0K	$496.0K	$496.0K
Prepaid Expenses
Receivables	$81.00K	$76.00K	$76.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$5.750M	$5.757M	$5.757M
YoY Change	-43.94%	-62.54%	-62.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$897.0K	$992.0K	$1.202M
YoY Change	-27.49%	-25.13%	-31.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$13.00K	$13.00K	$264.0K
YoY Change	0.0%	0.0%	-49.62%
Total Long-Term Assets	$1.316M	$1.466M	$1.466M
YoY Change	-33.33%	-35.62%	-35.62%
TOTAL ASSETS
Total Short-Term Assets	$5.750M	$5.757M	$5.757M
Total Long-Term Assets	$1.316M	$1.466M	$1.466M
Total Assets	$7.066M	$7.223M	$7.223M
YoY Change	-42.23%	-59.07%	-59.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.495M	$1.842M	$1.842M
YoY Change	1.56%	-6.45%	-6.45%
Accrued Expenses	$116.0K	$169.0K	$169.0K
YoY Change	-53.23%	-31.02%	-31.02%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.632M	$1.033M	$1.033M
YoY Change	-37.5%	-59.2%	-59.2%
Total Short-Term Liabilities	$3.309M	$3.270M	$3.270M
YoY Change	-24.42%	-31.86%	-31.86%
LONG-TERM LIABILITIES
Long-Term Debt	$669.0K	$1.239M	$1.239M
YoY Change	-82.86%	-73.0%	-85.39%
Other Long-Term Liabilities	$21.00K	$27.00K	$27.00K
YoY Change	-98.14%	-98.06%	-98.06%
Total Long-Term Liabilities	$669.0K	$1.239M	$1.266M
YoY Change	-82.86%	-73.0%	-87.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.309M	$3.270M	$3.270M
Total Long-Term Liabilities	$669.0K	$1.239M	$1.266M
Total Liabilities	$3.999M	$4.536M	$4.536M
YoY Change	-69.97%	-69.08%	-69.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$156.3M	-$154.2M
YoY Change	7.28%	9.05%
Common Stock	$1.000K	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.067M	$2.687M	$2.687M
YoY Change
Total Liabilities & Shareholders Equity	$7.066M	$7.223M	$7.223M
YoY Change	-42.23%	-59.07%	-59.07%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001686850
CY2023Q4	MOTS	Contingent Royalty Obligation ContingentRoyaltyObligation		usd
CY2023Q4	MOTS	Convertible Note Noncurrent ConvertibleNoteNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023	MOTS	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants		usd
CY2023	MOTS	Issuance Of Common Stock For Board Of Directors Compensation IssuanceOfCommonStockForBoardOfDirectorsCompensation		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse		usd
CY2022	MOTS	Loss On Lease Termination LossOnLeaseTermination		usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
CY2023	MOTS	Purchase Of Fixed Assets In Prepaid Expenses PurchaseOfFixedAssetsInPrepaidExpenses		usd
CY2023	MOTS	Purchase Of Property And Equipment In Accounts Payable And Accrued Expenses PurchaseOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses		usd
CY2022	MOTS	Noncash Issuance Costs From Private Placement NoncashIssuanceCostsFromPrivatePlacement		usd
CY2022	MOTS	Noncash Issuance Cost From Public Offering NoncashIssuanceCostFromPublicOffering		usd
CY2022	MOTS	Financing Fees Incurred But Unpaid At Period End FinancingFeesIncurredButUnpaidAtPeriodEnd		usd
CY2022	MOTS	Debt Issuance Costs Incurred But Unpaid At Period End DebtIssuanceCostsIncurredButUnpaidAtPeriodEnd		usd
CY2022	MOTS	Extinguishment Of Contingent Royalty Obligation ExtinguishmentOfContingentRoyaltyObligation		usd
CY2022	MOTS	Settlement Of Convertible Note To Equity SettlementOfConvertibleNoteToEquity		usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits		pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38389
CY2023	dei	Entity Registrant Name EntityRegistrantName	Motus GI Holdings, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-4042793
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1301 East Broward Boulevard
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	3rd Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Ft. Lauderdale
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33301
CY2023	dei	City Area Code CityAreaCode	(954)
CY2023	dei	Local Phone Number LocalPhoneNumber	541-8000
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	MOTS
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	3100000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5031376	shares
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	274
CY2023	dei	Auditor Name AuditorName	EISNERAMPER LLP
CY2023	dei	Auditor Location AuditorLocation	Iselin, New Jersey
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4958000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14042000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	76000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	59000	usd
CY2023Q4	MOTS	Inventory Current InventoryCurrent	245000	usd
CY2022Q4	MOTS	Inventory Current InventoryCurrent	488000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	478000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	781000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	5757000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	15370000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	992000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1325000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	251000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	511000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	210000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	428000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13000	usd
CY2023Q4	us-gaap	Assets Assets	7223000	usd
CY2022Q4	us-gaap	Assets Assets	17647000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1842000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1969000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	169000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	245000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	226000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	53000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	16000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	182000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1033000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2532000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3270000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4799000	usd
CY2022Q4	MOTS	Contingent Royalty Obligation ContingentRoyaltyObligation	1212000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	178000	usd
CY2023Q4	MOTS	Convertible Debt Unamortized Discount Noncurrent ConvertibleDebtUnamortizedDiscountNoncurrent	0	usd
CY2022Q4	MOTS	Convertible Debt Unamortized Discount Noncurrent ConvertibleDebtUnamortizedDiscountNoncurrent	108000	usd
CY2022Q4	MOTS	Convertible Note Noncurrent ConvertibleNoteNoncurrent	3892000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	108000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	135000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1239000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4589000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4536000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	14670000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	115000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	115000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1547042	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1547042	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	310494	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	310494	shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	156905000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	144328000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-154218000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141351000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2687000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2977000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7223000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17647000	usd
CY2023	us-gaap	Revenues Revenues	319000	usd
CY2022	us-gaap	Revenues Revenues	592000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	81000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	198000	usd
CY2023	MOTS	Costs Of Revenue Impairment Of Inventory CostsOfRevenueImpairmentOfInventory	488000	usd
CY2022	MOTS	Costs Of Revenue Impairment Of Inventory CostsOfRevenueImpairmentOfInventory	598000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3467000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5611000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1611000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4425000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6579000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7611000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	12226000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	18443000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-11907000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-17851000	usd
CY2023	MOTS	Gain Loss On Changes In Fair Value Of Contingent Royalty Obligation GainLossOnChangesInFairValueOfContingentRoyaltyObligation	-103000	usd
CY2022	MOTS	Gain Loss On Changes In Fair Value Of Contingent Royalty Obligation GainLossOnChangesInFairValueOfContingentRoyaltyObligation	-548000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-284000	usd
CY2023	MOTS	Finance Income Expense Net FinanceIncomeExpenseNet	761000	usd
CY2022	MOTS	Finance Income Expense Net FinanceIncomeExpenseNet	1252000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-18000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-42000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-12867000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18597000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-15.89
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-15.89
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-86.15
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-86.15
CY2023	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	809506	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	809506	shares
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	215863	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	215863	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9657000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9884000	usd
CY2022	MOTS	Stock Issued During Period Fractional Shares Settled In Cash Pursuant To Reverse Stock Split Value StockIssuedDuringPeriodFractionalSharesSettledInCashPursuantToReverseStockSplitValue	-11000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	235000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1809000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18597000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2977000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2977000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	102000	usd
CY2023	MOTS	Stock Issued During Period Value Private Placement Offering Net Of Financing Fees StockIssuedDuringPeriodValuePrivatePlacementOfferingNetOfFinancingFees	3070000	usd
CY2023	MOTS	Stock Issued During Period Value Issuance Of Common Share Upon Public Offering StockIssuedDuringPeriodValueIssuanceOfCommonShareUponPublicOffering	3875000	usd
CY2023	MOTS	Stock Issued During Period Value Issuance Of Common Shares Upon Extinguishment Of Contingent Royalty Obligation StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExtinguishmentOfContingentRoyaltyObligation	1071000	usd
CY2023	MOTS	Stock Issued During Period Value Settlement Of Convertible StockIssuedDuringPeriodValueSettlementOfConvertible	4000000	usd
CY2023	MOTS	Stock Issued During Period Fractional Shares Settled In Cash Pursuant To Reverse Stock Split Value StockIssuedDuringPeriodFractionalSharesSettledInCashPursuantToReverseStockSplitValue	-12000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	471000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-12867000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2687000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2687000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-12867000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18597000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	451000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	510000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	252000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	330000	usd
CY2023	MOTS	Gain Loss On Change In Estimated Fair Value Of Contingent Royalty Obligation GainLossOnChangeInEstimatedFairValueOfContingentRoyaltyObligation	103000	usd
CY2022	MOTS	Gain Loss On Change In Estimated Fair Value Of Contingent Royalty Obligation GainLossOnChangeInEstimatedFairValueOfContingentRoyaltyObligation	548000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	471000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1809000	usd
CY2022	MOTS	Issuance Of Common Stock For Board Of Directors Compensation IssuanceOfCommonStockForBoardOfDirectorsCompensation	235000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-284000	usd
CY2023	MOTS	Impairment Of Inventory ImpairmentOfInventory	488000	usd
CY2022	MOTS	Impairment Of Inventory ImpairmentOfInventory	598000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	46000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	226000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	327000	usd
CY2023	MOTS	Loss On Lease Termination LossOnLeaseTermination	11000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-50000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1302000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-283000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-12000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-454000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-650000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-241000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-330000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	20000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	43000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11194000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17467000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	104000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	224000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-104000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-224000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	121000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10252000	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3537000	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	5000000	usd
CY2023	MOTS	Fractional Shares Paid In Cash Pursuant To Reverse Stock Split FractionalSharesPaidInCashPursuantToReverseStockSplit	12000	usd
CY2022	MOTS	Fractional Shares Paid In Cash Pursuant To Reverse Stock Split FractionalSharesPaidInCashPursuantToReverseStockSplit	11000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4965000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	703000	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	200000	usd
CY2023	MOTS	Payments For Equity Financing Fees PaymentsForEquityFinancingFees	1267000	usd
CY2022	MOTS	Payments For Equity Financing Fees PaymentsForEquityFinancingFees	368000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2214000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9170000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9084000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8521000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14042000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22563000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4958000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14042000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	836000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	977000	usd
CY2023	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	14000	usd
CY2022	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	201000	usd
CY2022	MOTS	Purchase Of Fixed Assets In Prepaid Expenses PurchaseOfFixedAssetsInPrepaidExpenses	4000	usd
CY2022	MOTS	Purchase Of Property And Equipment In Accounts Payable And Accrued Expenses PurchaseOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses	24000	usd
CY2023	MOTS	Noncash Issuance Costs From Private Placement NoncashIssuanceCostsFromPrivatePlacement	264000	usd
CY2023	MOTS	Noncash Issuance Cost From Public Offering NoncashIssuanceCostFromPublicOffering	154000	usd
CY2023	MOTS	Financing Fees Incurred But Unpaid At Period End FinancingFeesIncurredButUnpaidAtPeriodEnd	228000	usd
CY2023	MOTS	Debt Issuance Costs Incurred But Unpaid At Period End DebtIssuanceCostsIncurredButUnpaidAtPeriodEnd	100000	usd
CY2023	MOTS	Extinguishment Of Contingent Royalty Obligation ExtinguishmentOfContingentRoyaltyObligation	1109000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	68000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	66000	usd
CY2023	MOTS	Settlement Of Convertible Note To Equity SettlementOfConvertibleNoteToEquity	4000000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_801_eus-gaap--NatureOfOperations_z73qfL7ZUtsf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_824_z83FxwbNwMF5">Description of Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motus GI Holdings, Inc. (the “Company”) was incorporated in Delaware, U.S.A. in September 2016. The Company and its subsidiaries, Motus GI Technologies, Ltd. and Motus GI, LLC, are collectively referred to as “Motus GI” or the “Company”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the “FDA”) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (“GI”) endoscopy procedures. The Pure-Vu System has received a CE Mark in the EU for use in colonoscopy. The Pure-Vu System integrates with standard and slim colonoscopes, as well as gastroscopes, to improve visualization during colonoscopy and upper GI procedures while preserving established procedural workflow and techniques. Through irrigation and evacuation of debris, the Pure-Vu System is designed to provide better-quality exams. The Company received 510(k) clearance in October 2023 from the FDA for the Pure-Vu EVS System for use in the upper GI tract and Gen 4 Colon and will commence market introduction of these products in the coming months. Both devices leverage the same workstation and feature key enhancements such as a larger and more powerful suction channel, more efficient irrigation jets, a smaller profile distal tip that offers enhanced flexibility during insertion, enhanced navigation and a much easier bed side set up. The Company does not expect to generate significant revenue from product sales until it further expands its commercialization efforts, which is subject to significant uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-12900000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5000000.0	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-154200000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_z9nDASeL0JS5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z9Mj8cjWwdXh">Basis of presentation and use of estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries, Motus Ltd., an Israel corporation, which has operations in Tirat Carmel, Israel, and Motus Inc., a Delaware corporation, which has operations in the U.S. All inter-company accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASUs, of the Financial Accounting Standards Board (“FASB”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On November 2, 2023, the Company effected a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-15.
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_z7Kq8JeUNAv4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zAhUnfKInb2">Concentrations of Credit Risk and Off-balance Sheet Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Revenues Revenues	319000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	295000	usd
CY2023	MOTS	Revenue Recognized In Accordance With Asc RevenueRecognizedInAccordanceWithAsc	24000	usd
CY2022	us-gaap	Revenues Revenues	592000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	540000	usd
CY2022	MOTS	Revenue Recognized In Accordance With Asc RevenueRecognizedInAccordanceWithAsc	52000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	67000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	39000	usd
CY2023	us-gaap	Payments For Commissions PaymentsForCommissions	0	usd
CY2022	us-gaap	Payments For Commissions PaymentsForCommissions	96000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
	MOTS	Rate Of Royalty Payment RateOfRoyaltyPayment	0.03	pure
CY2022	MOTS	Rate Of Royalty Payment RateOfRoyaltyPayment	0.03	pure
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	487000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	697000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	196000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	155000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	541000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	548000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	728000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	401000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	496000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	999000	usd
CY2023Q4	MOTS	Inventory Current InventoryCurrent	245000	usd
CY2022Q4	MOTS	Inventory Current InventoryCurrent	488000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	251000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	511000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	488000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	598000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3336000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3218000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2344000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1893000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	992000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1325000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	451000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	510000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	46000	usd
CY2023	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	Certain operating leases include escalation clauses and some of which may include options to extend the leases for up to 3 years
CY2023	MOTS	Operating Lease Cost Net OperatingLeaseCostNet	-29000	usd
CY2022	MOTS	Operating Lease Cost Net OperatingLeaseCostNet	92000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	178000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	120000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	161000	usd
CY2023	us-gaap	Lease Cost LeaseCost	310000	usd
CY2022	us-gaap	Lease Cost LeaseCost	212000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	210000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	428000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	169000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	245000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	178000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	196000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	423000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M4D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M14D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0730	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0736	pure
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	310000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	212000	usd
CY2023	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	270000	usd
CY2022	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	242000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	175000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	23000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	203000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	196000	usd
CY2022Q4	MOTS	Contingent Royalty Obligation ContingentRoyaltyObligation	1212000	usd
	MOTS	Gain Loss On Change In Estimated Fair Value Of Contingent Royalty Obligation GainLossOnChangeInEstimatedFairValueOfContingentRoyaltyObligation	103000	usd
CY2023Q3	MOTS	Contingent Royalty Obligation ContingentRoyaltyObligation	1109000	usd
CY2023Q3	MOTS	Contingent Royalty Obligation ContingentRoyaltyObligation	1109000	usd
	MOTS	Common Stock Exchanged For Extinguishment Of Royalty Obligation CommonStockExchangedForExtinguishmentOfRoyaltyObligation	-711000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	398000	usd
CY2023	MOTS	License Fees LicenseFees	270000	usd
CY2022	MOTS	License Fees LicenseFees	242000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	256000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	342000	usd
CY2023Q4	us-gaap	Interest Expense InterestExpense	211	usd
CY2022Q4	us-gaap	Interest Expense InterestExpense	128	usd
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	695000	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	1001000	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	252000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	330000	usd
CY2023	us-gaap	Interest Expense InterestExpense	947000	usd
CY2022	us-gaap	Interest Expense InterestExpense	1331000	usd
	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	1332000	usd
CY2023Q4	MOTS	London Interbank Offered Rate LondonInterbankOfferedRate	1439000	usd
CY2022Q4	MOTS	London Interbank Offered Rate LondonInterbankOfferedRate	1426000	usd
CY2023	MOTS	Royalties Percentage RoyaltiesPercentage	0.04	pure
CY2023Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	88221	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	8821	shares
CY2023	MOTS	Gain Loss On Settlement Equity Additional Paid In Capital GainLossOnSettlementEquityAdditionalPaidInCapital	<p id="xdx_89A_ecustom--GainLossOnSettlementEquityAdditionalPaidInCapital_zEyZA394ayO6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zyIEbmgjdqX9" style="display: none">Schedule of Extinguishment of Royalty Obligation</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20230101__20230912_znsMwdeWxbg4" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Extinguishment</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Royalty</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Obligation </b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_ecustom--ContingentRoyaltyObligation_i01S_pn3n3_maLzgSy_z3gfta3Kpt8e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Balance at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,212</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--GainLossOnChangeInEstimatedFairValueOfContingentRoyaltyObligation_i01N_pn3n3_di_msNCPBUzwDp_zzQflMw1tuo7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Change in estimated fair value of royalty obligation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(103</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_ecustom--ContingentRoyaltyObligation_i01E_pn3n3_maLzgSy_zmtdNTzZnQ8e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Balance at September 12, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">1,109</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--ContingentRoyaltyObligation_i01E_pn3n3_maLzgSy_zrwr4gxU7wv3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Contingent royalty obligation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,109</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--CommonStockExchangedForExtinguishmentOfRoyaltyObligation_i01N_pn3n3_di_zeQb40Avoohj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less fair value of common stock exchanged for extinguishment of royalty obligation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">711</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_pn3n3_zHAL85rnLsyb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Gain on extinguishment – recorded within additional paid-in-capital</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">398</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	471000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1809000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y4M2D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8066	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9921	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0293	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0210	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.96
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	129.30
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P2Y3M29D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	26	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35000	shares
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	40200000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	37400000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40200000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	37400000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2800000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	17943000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	14614000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	18740000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	18813000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	975000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1735000	usd
CY2023Q4	MOTS	Deferred Tax Asset Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetDeferredExpenseCapitalizedResearchAndDevelopmentCosts	2184000	usd
CY2022Q4	MOTS	Deferred Tax Asset Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetDeferredExpenseCapitalizedResearchAndDevelopmentCosts	1698000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	409000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	681000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	40251000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	37541000	usd
CY2023Q4	MOTS	Deferred Tax Liabilities Accelerated Research And Development Expense DeferredTaxLiabilitiesAcceleratedResearchAndDevelopmentExpense	52000	usd
CY2022Q4	MOTS	Deferred Tax Liabilities Accelerated Research And Development Expense DeferredTaxLiabilitiesAcceleratedResearchAndDevelopmentExpense	109000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	39000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	34000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	91000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	143000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	40160000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	37398000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40160000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	37398000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.007	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.066	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.008	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.008	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.058	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.027	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.019	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.080	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.107	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.106	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.150	pure
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	151400000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	134100000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	1800000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	10600000	usd
CY2021Q4	MOTS	Operating Loss Carryforwards Utilization Limitation OperatingLossCarryforwardsUtilizationLimitation	3700000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	35676000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	26875000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	34266000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	25464000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	81480000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	81794000	usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	151422000	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	134133000	usd
CY2023	MOTS	Expire Date Description ExpireDateDescription	begin to expire after 2036 through 2042
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.50
CY2023Q4	MOTS	Shares Issued Revised Price Per Share SharesIssuedRevisedPricePerShare	0.925
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4400001	shares
CY2023	us-gaap	Class Of Warrant Or Right Expense Or Revenue Recognized ClassOfWarrantOrRightExpenseOrRevenueRecognized	the terms of 2,933,334 Series A Common Warrants issued in December 2023 held by the same institutional investor to reduce the existing exercise price thereof from $1.50 to $0.74 per share and warrants to purchase up to 276,134 shares of Common Stock issued in May 2023 held by the institutional investor to reduce the existing exercise price thereof from $10.80 to $0.74

Files In Submission

Name	View Source	Status
mots-20231231_lab.xml	Edgar Link	unprocessable
0001493152-24-010314-index-headers.html	Edgar Link	pending
0001493152-24-010314-index.html	Edgar Link	pending
0001493152-24-010314.txt	Edgar Link	pending
0001493152-24-010314-xbrl.zip	Edgar Link	pending
endo_001.jpg	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex31-3.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
high_001.jpg	Edgar Link	pending
market_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mots-20231231.xsd	Edgar Link	pending
overview_001.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
mots-20231231_def.xml	Edgar Link	unprocessable
mots-20231231_pre.xml	Edgar Link	unprocessable
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
solution_001.jpg	Edgar Link	pending
solution_002.jpg	Edgar Link	pending
study_001.jpg	Edgar Link	pending
mots-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Motus GI Holdings, Inc.

2024 Q1 Form 10-K Financial Statement

#000149315224010314 Filed on March 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission